Nick G. Vatakis

Psychiatry
115 E 61st St Ste 2D
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.

A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.

Journal: The journal of headache and pain
Published: September 08, 2025
Showing 1-1 of 1

Last Updated: 09/26/2026